Visual summary only. The research findings, limitations and references accompany the card on this page.
The chemical drawing shows source-verified two-dimensional connectivity and stereochemistry, not an experimental three-dimensional conformation. The biological setting is an illustration. Original study diagrams summarize cited research without reproducing publication artwork or inventing quantitative results.
SNAP-8 / acetyl octapeptide-3
Proposed SNARE-related design
All-L N-acetyl octapeptide with C-terminal aspartamide; source parent without counterion- Molecular formula
- C41H70N16O16S
- Molecular weight
- 1075.2 g/mol
- Class
- Cosmetic octapeptide
- Identity
- Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2
Research snapshot
SNAP-8 is an eight-residue cosmetic ingredient related in sequence to Argireline. Its molecular identity can be specified, but the targeted PubMed search did not establish a standalone clinical evidence base for this ingredient.
Sparse compound-specific evidence
Identity & representation
Reference parent, not an AXON formulation or salt.
Educational reference only. Not a dosing guide, treatment recommendation or product endorsement.
Acetyl octapeptide-3 · Ac–Glu–Glu–Met–Gln–Arg–Arg–Ala–Asp–NH2[1]
View the chemical structure →Sources checked: 2026-11-06. Identity and evidence limits are stated above. Independent specialist review is pending.
What researchers study
SNAP-8 is an eight-residue cosmetic ingredient related in sequence to Argireline. Its molecular identity can be specified, but the targeted PubMed search did not establish a standalone clinical evidence base for this ingredient.
Cosmetic formulation development
Peptide identity and stability
Compound-specific efficacy evaluation
Mechanism in context
- Eight-residue acetylated peptide is formulated
- SNARE-related design rationale is proposed
- Compound-specific outcomes require direct testing
Sequence similarity to Argireline is not proof of the same mechanism, tissue access, clinical effect or safety. Manufacturer claims are distinct from independent trials.
Simplified publication-grounded schematic, not a solved protein structure or proof of clinical benefit.
Selected evidence
Sparse compound-specific evidence
Reference identity in detail
Sequences and form distinctions describe the cited reference substance, not a verified supplier preparation.
Research scope
Targeted source verification, not a systematic review. Citation quality and molecule-specific applicability are stated separately.
Safety & evidence limits
The targeted PubMed exact-name search returned no records; this is not a systematic proof that no study exists.
Do not borrow Argireline’s human results as SNAP-8 evidence.
Product mixtures and concentration claims do not establish the isolated peptide’s efficacy or safety.
Practical identity notes
- All-L N-acetyl octapeptide with C-terminal aspartamide; source parent without counterion
- No original PubChem 3D conformer was available for this exact reference in the checked endpoint; use exact 2D structure.
- Reference identity is not confirmation of product contents, purity, sterility or therapeutic equivalence.
- Reject PubChem71587832: source graph differs from expected sequence by a carbonyl-to-methylene substitution. Accepted76283482 independently matches Ac-EEMQRRAD-NH2.
The 10-second takeaway
A defined cosmetic octapeptide whose specific clinical evidence remains sparse; sequence similarity is not clinical validation.
What the visual panels show
Original diagrams summarize the cited research or documented evidence search. They are not copied publication figures or claims of treatment benefit.
EVIDENCE / IDENTITY CONTEXT[1][4][5]
Publication-grounded mechanism schematic · Original publication-grounded diagram
Eight-residue acetylated peptide · Sequence relationship to Argireline · Exact-compound evidence remains limited
Interpretation: Sequence similarity to Argireline is not proof of the same mechanism, tissue access, clinical effect or safety. Manufacturer claims are distinct from independent trials.
Two-residue sequence extension[1][4]
REFERENCE CHEMISTRY · Original publication-grounded diagram
SNAP-8 adds Ala–Asp to the Argireline sequence
Sequence similarity does not prove shared efficacy or target access.
Interpretation: Sequence similarity does not prove shared efficacy or target access. Original conceptual illustration only; no fabricated data, docking geometry or clinical extrapolation.
Identity and efficacy differ[2][5]
TARGETED LITERATURE REVIEW · Original publication-grounded diagram
Standalone clinical evidence is sparse
A query-limited review, not proof that no research exists anywhere.
Interpretation: A query-limited review, not proof that no research exists anywhere. Original conceptual illustration only; no fabricated data, docking geometry or clinical extrapolation.
Ingredient versus solution[3]
MANUFACTURER IDENTITY · Original publication-grounded diagram
A formulated solution is not one molecule
Manufacturer claims are distinct from independent clinical trials.
Interpretation: Manufacturer claims are distinct from independent clinical trials. Original conceptual illustration only; no fabricated data, docking geometry or clinical extrapolation.
Follow the evidence
Sources & what they support
- PubChem CID 76283482: source reference graph
Supports: Exact reference graph, stereochemistry, formula and mass
Original structure record · Download source SDF
Original PubChem 2D source structure record.
- NIH GSRS acetyl octapeptide-3 identity
Supports: Ingredient registry identity, not drug approval
- SNAP-8 peptide solution C manufacturer record
Supports: Trade-name to acetyl octapeptide-3 identity; solution is a mixture
- A synthetic hexapeptide (Argireline) with antiwrinkle activity.
Supports: Related hexapeptide comparison only; not evidence for SNAP-8
- Targeted exact-name PubMed search
Supports: Evidence-gap check; raw ESearch response retained
← Explore the Molecular Atlas Continue to the research library →
